Search

Displaying results 8691 - 8700 of 10000 in total
  1. Drug

    Fiboflapon

    go.drugbank.com/drugs/DB06346
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. … of a SERD represents a therapeutic approach for the treatment of endocrine-resistant breast cancers.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol
  3. Drug

    Talnetant

    go.drugbank.com/drugs/DB06429
    Investigational

    Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several different functions, primarily for irritable bowel syndrome and as a potential

    Categories: Heterocyclic Compounds, 2-Ring, Receptors, Neurokinin-3, antagonists & inhibitors
  4. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

    Salts: R-1487 hydrochlorideCategories: Heterocyclic Compounds, 1-Ring
  6. Drug

    Mitemcinal

    go.drugbank.com/drugs/DB06587
    Investigational

    Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  7. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    Vicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1. … This pyrimidine based drug inhibits the interaction of HIV-1 with CCR5, preventing viral entry into cells. This drug was developed by Schering-Plough.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  8. Drug

    Clazosentan

    go.drugbank.com/drugs/DB06677
    Investigational

    Categories: Receptor, Endothelin A, Heterocyclic Compounds, 1-Ring
  9. Drug

    Clevudine

    go.drugbank.com/drugs/DB06683
    Investigational

    Synonyms: 2'-Fluoro-5-methyl-beta-L-arabinofuranosyluracil, L-FMAUCategories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Vilazodone

    go.drugbank.com/drugs/DB06684
    ApprovedInvestigational

    Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622].

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring